Insider · SEC Form 4 filer

Broadwood Partners, L.P.

Companies

Where they file as an insider

Insight Molecular Diagnostics (IMDX) 10% owner Latest filing Apr 27, 2026
Staar Surgical (STAA) 10% owner Latest filing Apr 7, 2025
Lineage Cell Therapeutics (LCTX) Director, 10% owner Latest filing Feb 6, 2024

Track record

Did their buys beat the typical stock?

Open-market buys1
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check0

Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.

Lineage Cell Therapeutics (LCTX) Bought Feb 6, 2024 · $7M · 6.73M shares Behind typical Mar 31, 2024 $1.48 → Sep 30, 2024 $0.91 · −38.8% (typical stock +3.2%)

Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.

Past results. This is data, not advice.

Where this data comes from. Insider trades, fund holdings, activist stakes and company results come from public SEC EDGAR filings (Forms 4, 13F, 13D/13G, 10-Q and 8-K). Congress trades come from the STOCK Act reports members file with the House Clerk and the Senate. Daily closing prices come from post-no-preference/stocks on DoltHub, a community-run database shared under CC BY-SA 4.0; the prices we show stay under that license. They are each day's close, not live or official exchange prices.

This is data, not investment advice. About StockToast · Your watchlist